Navigation Links
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
Date:10/31/2013

ated to a breach of contract and other existing disputes; and 3) restructuring, integration and other charges of $305 million primarily related to the acquisition of Bausch + Lomb. 

On a Cash EPS basis, adjusted income was $486 million, or $1.43 per diluted share, an increase of 24% over the prior year.  Excluding the pre-closing financing costs and increased share count associated with the financing of the Bausch + Lomb transaction, Cash EPS would have been $1.51, or an increase of 31% over the prior year.  In addition, the unexpected early launch of a generic competitor to Retin-A Micro following Valeant's second quarter financial results conference call negatively impacted Cash EPS by $0.04 and the strengthening of the dollar against many of our major currencies negatively cost the Company an additional $0.03 in the third quarter.

GAAP cash flow from operations was $202 million in the third quarter of 2013, and adjusted cash flow from operations was $408 million, an increase of 69% over the prior year. This increase in adjusted cash flow from operations was driven by growth across all our businesses, offset by an investment in working capital due to the Bausch + Lomb acquisition.

The Company's cost of goods sold (COGS) was $561 million in the third quarter of 2013.  After backing out the fair value adjustment to inventory, amortization expense and other items related to acquisitions, COGS represented 27% of product sales, an increase of four percentage points as compared to the third quarter of 2012 due to the acquisition of Bausch + Lomb which has a higher COGS profile.

Selling, General and Administrative expenses were $356 million in the third quarter of 2013 which includes a $4 million step-up in stock based compensation expenses.  Excluding these expenses, SG&A was approximately 23% of revenue.  Research and Development expenses were $49 million in the third quarter of 2013, or approximately 3%
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis - ... Sepsis patients suffer from a series of diverse complications ... in the blood or tissues, which cause a rapidly ... to mortality rates near 50% depending on disease severity. ... healthcare systems of the global marketplace, which for the ...
(Date:5/27/2015)... -- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - ... Event-Driven Update Summary The lupus therapeutics ... the only drug that has gained marketing approval for ... patients, uptake has remained low, but due to its ... lupus market in terms of value and is currently ...
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "Asia Pacific Ultrasound Devices ... - 2019)"  company profile to their ... , ,Ultrasound is a type of imaging. ... at body parts and structures inside the ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... Meg Porfido, former chief human resources officer for Level ... Directors for Kaiser Foundation Hospitals and Kaiser Foundation Health ... to our Board will further diversify the outstanding talents ... George C. Halvorson, chairman and chief executive officer of ...
... 2011 Varian Medical Systems (NYSE: VAR ... system vendors in a 2011 performance report released last ... monitoring and reporting on the performance of healthcare technology ... a range of clinical, administrative, and financial activities in ...
Cached Medicine Technology:Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors 2Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors 3Varian Medical Systems' ARIA Ranked No. 1 in 2011 KLAS Report on Oncology IT Vendors 2Varian Medical Systems' ARIA Ranked No. 1 in 2011 KLAS Report on Oncology IT Vendors 3
(Date:5/27/2015)... Nursing Homes are starting to supplant hospitals as focus of ... April 2015 New York Times article. While Americans, in practice, ... years of research have documented the risks of hospitalization for ... both safer for older patients and less costly than hospitals. ... patients and family members may worry whether a nursing home ...
(Date:5/27/2015)... May 27, 2015 With the launch ... more robust Network Management Module (NMM) tool, monitoring provider-network ... 21 issue of Atlantic Information Services, Inc.’s (AIS) Medicare ... NMM tool, as well as analysis from industry experts ... The changes coming to the NMM were announced at ...
(Date:5/27/2015)... Marcos, CA (PRWEB) May 27, 2015 Allred ... solution to help patients - who need extensive dental treatment ... well as treatment options customized for their problems. , Dr. ... in a visual presentation of the assessment of the patient’s ... suitable options, which can treat their oral health problems. , ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a leading ... announced today that SanMar Corporation successfully implemented the ... and point tracking processes for over 3,000 employees ... , Family-owned since 1971, Seattle-based SanMar Corporation is ... and mill brands. SanMar supplies apparel and accessories ...
(Date:5/27/2015)... 2015 CURE® Magazine and ... mission is to advance research, provide information and support, ... to battle the fifth most common type of cancer, ... start to grow out of control. , “CURE ... every stage of the cancer experience through digital and ...
Breaking Medicine News(10 mins):Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3
... perform with, it would be British band Coldplay. ... and that's why he would give an arm and a leg ... Timberlake knows just who he wants to jam with - Gwyneth ... so I'd love to do a duet with them - especially ...
... systems have been deployed worldwide to provide early detection ... ,New methods that improve the overall detection capabilities ... However, most surveillance systems do not hold up when ... caused by public-health crises and major public events, such ...
... and Hull York Medical School has confirmed a link between ... is a vitamin that comes from vegetables such as spinach ... sunflower seeds as well as liver are rich sources of ... to bread or flour will decrease the number of babies ...
... shows that the work intended for global health is ... ,The research was conducted by a UW team including ... the School of Public Health and Community Medicine; Jennifer ... Weatherford, finance and administration director of the Department of ...
... of alcohol has found that a high percentage of ... youth .Many high school students consume alcohol both regularly ... sources of alcohol, individuals who illegally provide alcohol to ... ,Many types of social sources of alcohol are used ...
... review shows how nicotine patches can double ... that the antidepressants bupropion and nortriptyline aid long-term ... (e.g. fluoxetine) do not. ,Yet another ... UK by NICE), increased the odds of successful ...
Cached Medicine News:Health News:Global Health Enriching the States Economy 2Health News:Underage Youth Get Alcohol from Social Sources 2Health News:Underage Youth Get Alcohol from Social Sources 3
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: